Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Human Metabolome TechnologiesTSE:6090 +3.37%62 EBITDA Margin % is 36.35% as of Mar. 2026, which is 517% above its 10-year median of 5.89. GuruFocus rates TSE:6090 with a GF Score™ of 62/100 and a GF Value™ of 円693.69 (Fairly Valued). The stock has 3 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Human Metabolome Technologies ranks better than 84.65% on this metric.
Human Metabolome Technologies (TSE:6090) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Human Metabolome Technologies EBITDA Margin % Related Terms
Human Metabolome Technologies EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies EBITDA Margin % Chart
TSE:6090 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Human Metabolome Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies (TSE:6090) has a EBITDA Margin % of 36.35% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Human Metabolome Technologies and its competitors. This is 517% above median its historical median of 5.89. According to the industry distribution chart, Human Metabolome Technologies ranks #31 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 15.3%.
Is Human Metabolome Technologies' EBITDA Margin % too high?
Human Metabolome Technologies' current EBITDA Margin % of 36.35% is 517% above median its 10-year median of 5.89. The Medical Diagnostics & Research industry median EBITDA Margin % is 6.22. Human Metabolome Technologies' value of 36.35% is 484.9% above this industry median. Based on the distribution chart, Human Metabolome Technologies ranks #31 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Human Metabolome Technologies has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #31 out of 202 companies for EBITDA Margin %. This places Human Metabolome Technologies in the top 15% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 6.22. Human Metabolome Technologies' value of 36.35% is 484.9% above this benchmark. While the company's 10-year median is 5.89 vs. the industry median of 6.22, Human Metabolome Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 6.22, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Human Metabolome Technologies's current EBITDA Margin % of 36.35% is 484.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Human Metabolome Technologies and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 6.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Human Metabolome Technologies's current EBITDA Margin % is 36.35%, which is 517% above median its own 10-year median of 5.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Fairly Valued. The stock's GF Value™ is 円693.69, compared to a current price of 円645.00 — trading 7% below its estimated fair value. The current EBITDA Margin % is 36.35%, which is 517% above median its 10-year median of 5.89 and 484.9% above the Medical Diagnostics & Research industry median of 6.22. Human Metabolome Technologies' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current EBITDA Margin % is 36.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be undervalued.
The current stock price of 円645.00 is trading 7% below its estimated GF Value™ of 円693.69.
GuruFocus considers Human Metabolome Technologies to be Fairly Valued.
Key valuation signals for TSE:6090:
EBITDA Margin %: 36.35% (517% above median its 10-year median of 5.89)
GF Value™: 円693.69 vs. price of 円645.00 (7% below fair value)
Industry Position: 484.9% above the Medical Diagnostics & Research median (#31 of 202)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
